Hebei Senlang Biotechnology Inc., Ltd.
4 clinical trials · 4 recruiting · INDUSTRY
Trials by Hebei Senlang Biotechnology Inc., Ltd.
RECRUITINGNCT05626400
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic...
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.Enrolling: 1001 location
T-cell Acute Lymphoblastic Leukemia/Lymphoma
RECRUITINGPhase 1NCT06136364
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.Enrolling: 91 location
T-lymphoblastic LymphomaT-ALL
RECRUITINGNCT05618041
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.Enrolling: 501 location
Acute Lymphoblastic LeukemiaLymphomaMultiple Myeloma
RECRUITINGEarly Phase 1NCT07435779
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative...
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.Enrolling: 121 location
UC